Advances in the Management of Malignant Hemopathies: The Role of Statins
Affiliation: Clinica Medicala II, Spitalul Clinic Judetean, B-dul Corneliu Coposu, Nr 2-4, 2400 Sibiu, Romania.
Keywords: Atorvastatin, cytarabine, dipyridamole, gene expression profile, geranyl-geranylation, idarubicine, imatinib
mesylate, leukemia, lymphoma, myopathy, pravastatin, retinoids, rituximab, simvastatin, statin, thrombin
Today, hematology is dependent on molecular biology for diagnosis, establishing the prognosis and treatment
guidance in more and more diseases. One useful technique in this respect is the gene expression profiling, whose use is
not yet a matter of routine. The discovery that the expression of LDL-receptor and cholesterol synthesis is increased in the
cells of some leukemias and lymphomas and that some statins induced DNA damages and increased the level of reactive
oxygen species, opens the possibility of using statins in the treatment of certain malignant hemopathies. Patents regarding
their association with dipyridamole, retinoids, tipifarnib, cytostatics or chemotherapy programs contribute to increasing
their effectiveness. Statins can increase the apoptosis of malignant cells and restore the chemosensitivity in patients with
different malignant hemopathies. Techniques of molecular biology are useful for identifying patients who have indication
for statins. The main adverse effects of statins are increased transaminase levels and myopathy. The last may be
anticipated and treated today.
Rights & PermissionsPrintExport